12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Phenex, J&J deal

Phenex and Johnson & Johnson's Janssen Biotech Inc. subsidiary partnered to discover compounds against RAR-related orphan receptor C thymus-specific isoform ( RORgamma2; RORgammaT) to treat chronic...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >